Recent progress in direct-acting antiviral agents for chronic hepatitis C / 临床肝胆病杂志
Journal of Clinical Hepatology
; (12): 493-495, 2014.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-498959
Biblioteca responsável:
WPRO
ABSTRACT
The current standard treatment for hepatitis C virus (HCV)infection is a combination of pegylated interferon (PEG-IFN)and ribavirin.However,it remains incurable in some patients.In recent years,direct acting antiviral agents (DAAs)that target specific HCV enzymes in HCV life cycle have been developed rapidly.A combination of PEG-IFN,ribavirin,and DAAs can increase the sustained viro-logical response rate in patients with chronic hepatitis C (CHC).For patients who cannot use or tolerate interferon therapy,a combination of various DAAs has good efficacy.Therefore,DAAs bring new hope for the treatment of CHC.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Journal of Clinical Hepatology
Ano de publicação:
2014
Tipo de documento:
Artigo